Van Lanschot Kempen Investment Management’s Atlas Corp. ATCO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-566,958
Closed -$8.32M 224
2022
Q1
$8.32M Sell
566,958
-167,755
-23% -$2.48M 0.25% 96
2021
Q4
$10.4M Sell
734,713
-17,782
-2% -$251K 0.32% 91
2021
Q3
$11.4M Sell
752,495
-88,166
-10% -$1.26M 0.41% 83
2021
Q2
$12M Buy
840,661
+40,752
+5% +$566K 0.43% 74
2021
Q1
$10.9M Sell
799,909
-38,417
-5% -$492K 0.5% 76
2020
Q4
$9.09M Sell
838,326
-135,243
-14% -$1.39M 0.53% 74
2020
Q3
$8.7M Sell
973,569
-303,990
-24% -$2.47M 0.66% 67
2020
Q2
$9.71M Buy
1,277,559
+107,340
+9% +$781K 0.71% 62
2020
Q1
$9M Buy
1,170,219
+284,067
+32% +$3.13M 0.75% 56
2019
Q4
$12.6M Sell
886,152
-251,480
-22% -$3M 0.79% 54
2019
Q3
$12.1M Buy
1,137,632
+174,819
+18% +$1.82M 0.96% 46
2019
Q2
$9.45M Buy
962,813
+198,689
+26% +$1.91M 0.82% 53
2019
Q1
$6.65M Buy
+764,124
New +$6.66M 0.6% 64

Other funds holding ATCO

Van Lanschot Kempen Investment Management's ATCO Position: Q2 2022 in Review

Van Lanschot Kempen Investment Management sold out of Atlas Corp. (ATCO) in Q2 2022, closing a stake of 566,958 shares — an estimated $8.32M sold.

Van Lanschot Kempen Investment Management first reported a position in ATCO in Q1 2019 and held it in 13 quarters. The position peaked at $12.6M in Q4 2019. 150 funds tracked by Wall St. Rank hold ATCO as of Q2 2022.

  • Van Lanschot Kempen Investment Management reported no remaining Atlas Corp. position as of Q2 2022 after selling out during the quarter.
  • Van Lanschot Kempen Investment Management sold 566,958 Atlas Corp. shares in Q2 2022, an estimated $8.32M.
  • Van Lanschot Kempen Investment Management first reported a position in Atlas Corp. in Q1 2019 and held it in 13 quarters.
  • Van Lanschot Kempen Investment Management's Atlas Corp. position peaked at $12.6M in Q4 2019.
  • 150 funds tracked by Wall St. Rank held Atlas Corp. as of Q2 2022.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.